SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (48)9/8/2000 7:01:34 AM
From: scott_jiminez  Read Replies (1) of 278
 
Nigel - I forgot to mention: if you're interested in pursuing the neural stem cell story on the biotech/business front, two of the leading companies are 1. Layton Bioscience (http://www.laytonbio.com/) and 2. Diacrin (http://www.diacrin.com/).

I am not endorsing these companies nor do I have a grasp of the integrity of their science (Diacrin recently had a porcine cell-transplant study for stroke put on hold due to complications in some of the patients).

One other point about CNS stem cell therapy: a good deal of the success reported by Bjorklund et al. (in fetus-derived, dopaminergic (DA) cell replacement for Parkinson's (PD) patients) is believed to be the result of 'supporting cells - glia, non-DA neurons - which are part of the fetal graft and which help provide a rough approximation of the appropriate microenvironment for the DA cells to survive and function correctly. When preparing neural stems cells for a similar graft, the population consists almost entirely of the stem cells i.e. devoid of the 'contaminating' cells which, in the end, appear to be critical for significant functional enhancement.

The studies that I'm familiar (rodent) suggest that the inter-study variability of positive functional outcomes is much higher with stem cell-derived DA neurons than similar work using 'normally' differentiated DA neurons from fetal tissue. The fetal cells consistently produce significantly higher rates of functional recovery in animal models of PD.

Scott
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News